35.172.223.251
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-
Retina

Chart-based visual function tests may be considered as measures for clinical trial end point in AMD

Posted on June 24, 2022

The repeatability of 5 chart-based visual assessments, including best-corrected visual acuity (BCVA), low-luminance visual acuity (LLVA), Moorfields Acuity Test (MAT), Pelli-Robson Contrast Sensitivity (CS), and International Reading Speed Test (IReST), was found to adequate in patients with age-related macular degeneration (AMD) with limited power to discriminate between no AMD and intermediate AMD (iAMD), according to a study published in JAMA Ophthalmology.

These tests may be considered as potential measures for clinical trial end points.

A total of 301 participants, 34 with early AMD, 168 with iAMD, 43 with late AMD, and 56 with no AMD, were included in this cross-sectional study.

When considering all participants, intraclass correlation coefficients for all visual function measures ranged between 0.88 and 0.96. On all measures, there was excellent discrimination between iAMD and late AMD but early AMD was not able to be distinguished from iAMD.

CS had the best discrimination between no AMD and iAMD, whereas BCVA, LLVA, and MAT had fair discrimination and IReST had poor discrimination.

Reference
Dunbar HMP, Behning C, Abdirahman A, et al. Repeatability and Discriminatory Power of Chart-Based Visual Function Tests in Individuals With Age-Related Macular Degeneration: A MACUSTAR Study Report. JAMA Ophthalmol.  2022;doi:10.1001/jamaophthalmol.2022.2113

-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-